Arix Bioscience
Arix Bioscience, a leading life sciences company headquartered in Great Britain, focuses on advancing innovative therapies in the biotechnology sector. Founded in 2013, Arix has established itself as a key player in the industry, with a strong emphasis on developing and commercialising breakthrough treatments across various therapeutic areas, including oncology and rare diseases. The company is renowned for its unique approach to building and supporting a diverse portfolio of life science companies, leveraging its deep expertise and extensive network. Arix Bioscience's commitment to fostering innovation has positioned it as a prominent venture capital firm, recognised for its strategic investments and successful partnerships. With a robust pipeline of core products and a reputation for excellence, Arix continues to make significant strides in transforming healthcare and improving patient outcomes.
DitchCarbon Score
How does Arix Bioscience's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Arix Bioscience's score of 27 is higher than 84% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Arix Bioscience's reported carbon emissions
In 2022, Arix Bioscience, headquartered in Great Britain, reported total carbon emissions of approximately 8,890 kg CO2e. This figure includes 3,680 kg CO2e from Scope 1 emissions and 4,410 kg CO2e from Scope 2 emissions, with a total market-based Scope 2 emission of 8,890 kg CO2e. Additionally, Scope 3 emissions were recorded at about 5,210 kg CO2e. Comparatively, in 2021, the company emitted around 7,800 kg CO2e in total, with 4,860 kg CO2e from Scope 1 and 2,670 kg CO2e from Scope 2. This indicates a rise in emissions from 2021 to 2022, highlighting the need for enhanced climate strategies. Arix Bioscience has not publicly committed to specific reduction targets or initiatives, nor have they aligned with the Science Based Targets initiative (SBTi) for emissions reduction. The absence of defined reduction strategies suggests a potential area for improvement in their climate commitments. Overall, Arix Bioscience's emissions data reflects the company's current environmental impact, while the lack of reduction targets indicates an opportunity for future climate action.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2017 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|
| Scope 1 | 14,100 | 0,000 | 0,000 | 0,000 |
| Scope 2 | 7,000 | 0,000 | 0,000 | 0,000 |
| Scope 3 | - | 00 | 0,000 | 0,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Arix Bioscience is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
